The role of myokines in muscle health and disease

Current Opinion in Rheumatology

Volumn 28, Issue 6, 2016, Pages 661-666

  Lightfoot, Adam P ^a   Cooper, Robert G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cytokines; Idiopathic inflammatory myopathies; Myokines; Myositis; Skeletal muscle

Indexed keywords

CHEMOKINE; CYTOKINE; DECORIN; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; MYOKINE; MYOSTATIN; UNCLASSIFIED DRUG; DCN PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MSTN PROTEIN, HUMAN;

APOPTOSIS; DOWN REGULATION; EXERCISE; HUMAN; MUSCLE CELL; MUSCLE HYPERTROPHY; MYOSITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; METABOLISM; MUSCLE DISEASE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE CELL;

CYTOKINES; DECORIN; EXERCISE; HUMANS; INTERLEUKIN-6; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOSTATIN; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84983485892     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000337     Document Type: Review

References (49)

1. Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics 2010; 73:1896-1906.
2. Karagiannis GS, Pavlou MP, Diamandis EP. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol 2010; 4:496-510.
3. Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015; 522:106-110.
4. Ostrowski K, Rohde T, Zacho M, et al. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998; 508:949-953.
5. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunolo-gically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113:407-414.
6. Bhatnagar S, Panguluri SK, Gupta SK, et al. Tumor necrosis factor-alpha regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS One 2010; 5:e13262.
7. Yoon JH, Kim J, Song P, et al. Secretomics for skeletal muscle cells: a discovery of novel regulators? Adv Biol Regul 2012; 52:340-350.
8. Bortoluzzi S, Scannapieco P, Cestaro A, et al. Computational reconstruction of the human skeletal muscle secretome. Proteins 2006; 62:776-792.
9. Henningsen J, Rigbolt KT, Blagoev B, et al. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 2010; 9:2482-2496.
10. Hartwig S, Raschke S, Knebel B, et al. Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014; 1844:1011-1017.
11. Luo G, Hershko DD, Robb BW, et al. IL-1beta stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-kappa B. Am J Physiol Regul Integr Comp Physiol 2003; 284:R1249-R1254.
12. 2+-dependent mechanisms. Am J Physiol Cell Physiol 2007; 293:C1139-C1147.
13. Peake JM, Suzuki K, Hordern M, et al. Plasma cytokine changes in relation to exercise intensity and muscle damage. Eur J Appl Physiol 2005; 95:514-521.
14. Steensberg A, Fischer CP, Keller C, et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003; 285:E433-E437.
15. Kosmidou I, Vassilakopoulos T, Xagorari A, et al. Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. Am J Respir Cell Mol Biol 2002; 26:587-593.
16. Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005; 64:1257-1262.
17. Lightfoot AP, Sakellariou GK, Nye GA, et al. SS-31 attenuates TNF-a induced cytokine release from C2C12 myotubes. Redox Biol 2015; 10:253-259.
18. Perrin L, Loizides-Mangold U, Skarupelova S, et al. Human skeletal myotubes display a cell-autonomous circadian clock implicated in basal myokine secre-tion. Mol Metab 2015; 4:834-845.
19. Starkie R, Ostrowski SR, Jauffred S, et al. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003; 17:884-886.
20. Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014; 15:423-430.
21. Wong PK, Campbell IK, Egan PJ, et al. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003; 48:1177-1189.
22. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98:911-917.
23. Pedersen BK, Fischer CP. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 2007; 10:265-271.
24. Febbraio MA, Hiscock N, Sacchetti M, et al. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53:1643-1648.
25. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10:720-727.
26. Covington JD, Tam CS, Bajpeyi S, et al. Myokine expression in muscle and myotubes in response to exercise stimulation. Med Sci Sports Exerc 2016; 48:384-390.
27. Yeo NH, Woo J, Shin KO, et al. The effects of different exercise intensity on myokine and angiogenesis factors. J Sports Med Phys Fitness 2012; 52:448-454.
28. Gill N, Paltser G, Ashkar AA. Interleukin-15 expression affects homeostasis and function of B cells through NK cell-derived interferon-gamma. Cell Immunol 2009; 258:59-64.
29. McInnes IB, Leung BP, Sturrock RD, et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3:189-195.
30. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995; 136:3669-3672.
31. Quinn LS, Anderson BG, Drivdahl RH, et al. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res 2002; 280:55-63.
32. Nielsen AR, Mounier R, Plomgaard P, et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol 2007; 584:305-312.
33. Carbo N, Lopez-Soriano J, Costelli P, et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 2001; 1526:17-24.
34. Figueras M, Busquets S, Carbo N, et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 2004; 569:201-206.
35. Harcourt LJ, Holmes AG, Gregorevic P, et al. Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005; 166:1131-1141.
36. Pistilli EE, Alway SE. Systemic elevation of interleukin-15 in vivo promotes apoptosis in skeletal muscles of young adult and aged rats. Biochem Biophys Res Commun 2008; 373:20-24.
37. Pistilli EE, Bogdanovich S, Garton F, et al. Loss of IL-15 receptor alpha alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. J Clin Invest 2011; 121:3120-3132.
38. Henningsen J, Pedersen BK, Kratchmarova I. Quantitative analysis of the secretion of the MCP family of chemokines by muscle cells. Mol Biosyst 2011; 7:311-321.
39. Lightfoot AP, Goljanek-Whysall K, Earl KE, et al. Is muscle a chemotactic organ in the idiopathic inflammatory myopathies (IIM)? Overexpression of MHC I (H-2Kb) in C2C12 myotubes results in release of pro-inflammatory cytokines. Rheumatology (Oxford) 2015; 54:i43.
40. Warren GL, Hulderman T, Mishra D, et al. Chemokine receptor CCR2 involvement in skeletal muscle regeneration. FASEB J 2005; 19:413-415.
41. Kanzleiter T, Rath M, Gorgens SW, et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem Biophys Res Commun 2014; 450:1089-1094.
42. Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014; 83:2239-2246.
43. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52:1824-1835.
44. Lightfoot AP, Nagaraju K, McArdle A, Cooper RG. Understanding the origin of non immune-cell mediated weakness in the idiopathic inflammatory myopa-thies (IIM)-potential role of ER stress-pathways. Curr Opin Rheumatol 2015; 27:580-585.
45. Welc SS, Judge AR, Clanton TL. Skeletal muscle interleukin-6 regulation in hyperthermia. Am J Physiol Cell Physiol 2013; 305:C406-C413.
46. Kim S, Joe Y, Kim HJ, et al. Endoplasmic reticulum stress-induced IRE1alpha activation mediates cross-talk of GSK-3beta and XBP-1 to regulate inflammatory cytokine production. J Immunol 2015; 194:4498-4506.
47. Coley W, Rayavarapu S, Pandey GS, et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthritis Rheum 2012; 64:3750-3759.
48. Alemo-Munters L, Loell I, Ossipova E, et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheum 2016; 68:1738-1750.
49. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol 2015; 11:86-97.